1. Home
  2. SRL vs ACOG Comparison

SRL vs ACOG Comparison

Compare SRL & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scully Royalty Ltd.

SRL

Scully Royalty Ltd.

HOLD

Current Price

$6.13

Market Cap

96.5M

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

N/A

Current Price

$5.99

Market Cap

110.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SRL
ACOG
Founded
2017
2000
Country
China
Canada
Employees
N/A
57
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
96.5M
110.4M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
SRL
ACOG
Price
$6.13
$5.99
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
12.8K
33.9K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
16.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$139.22
Revenue Next Year
N/A
$134.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$4.50
52 Week High
$10.39
$10.88

Technical Indicators

Market Signals
Indicator
SRL
ACOG
Relative Strength Index (RSI) 28.74 47.54
Support Level $5.37 $5.73
Resistance Level $6.44 $6.48
Average True Range (ATR) 0.35 0.40
MACD -0.02 -0.02
Stochastic Oscillator 48.57 50.43

Price Performance

Historical Comparison
SRL
ACOG

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: